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a b s t r a c t
Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and
post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this
burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to
support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote
consistency in observational studies and surveillance, to better establish disease burden. The World
Health Organization convened a working group to provide consensus guidance for case ascertainment
and case definitions of GBS disease in stillbirths, infants, pregnant and post-partumwomen, with feedback
sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS
disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical
assessment, standardised sampling strategies and optimised laboratorymethods. Confirmed cases of inva-
sive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine
efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional
endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women
should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases,
however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal
and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional,
separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease out-
comes, intervention studies also present an opportunity to establish the contribution of GBS across
adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy.
 2019 Published by Elsevier Ltd.
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0264-410X/ 2019 Published by Elsevier Ltd.
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1. Introduction
1.1. Burden of disease and interventions
Group B Streptococcus (GBS) causes invasive disease in pregnant
and post-partum women, infants and fetuses, resulting in maternal
and infant disease, death or disability, and stillbirth. Recent annual
estimates of 319,000 (uncertainty range (UR) = 119,000–417,000)
infant GBS cases and 90,000 (UR = 41,000–185,000) infant GBS
deaths worldwide [1] are higher than those for other diseases for
which maternal vaccines are recommended or are further along
in development, such as influenza and respiratory syncytial virus.
In addition, although data are limited, it is conservatively esti-
mated that 57,000 (UR 12,000–104,000) stillbirths are associated
with GBS, and 33,000 (UR = 13,000–52,000) pregnant or puerperal
women have GBS sepsis each year [1]. For those infants that sur-
vive GBS disease, there can be long term neurodevelopmental
impairment (NDI) [2], however, data are currently insufficient to
estimate this burden beyond NDI associated with GBS meningitis.
Maternal GBS colonisation can also be associated with preterm
birth, but data are also insufficient to quantify this [3].
The reservoir for GBS in humans is the gastrointestinal tract and
maternal recto-vaginal colonisation is necessary for ascending fetal
infection and stillbirth/early onset GBS disease (EOGBS, days 0–6
after birth). In some high- and middle-income settings, maternal
recto-vaginal colonisation has been used to guide intrapartum
antibiotic prophylaxis (IAP) to prevent early-onset GBS disease
[4,5], based on either microbiological detection of GBS or the pres-
ence of clinical risk-factors. However, whilst reductions in EOGBS
in the USA have been observed [6], IAP does not prevent late onset
GBS disease (LOGBS, days 7–89) [7] and is unlikely, given the tim-
ing of prophylaxis, to impact on stillbirth or preterm birth. The
development of GBS vaccines suitable for maternal immunization
in pregnancy and use in low- and middle-income countries (LMICs)
has been identified as a priority by the World Health Organization
(WHO). Key consensus documents, highlighting preferences for
GBS vaccine product characteristics and providing a research and
development technical roadmap, have been developed to acceler-
ate vaccine availability [8–10].
Recent Brighton Collaboration guidelines have been developed
for defining neonatal infection [11], but strengthening of case cap-
ture methodologies and definitions of specific clinical endpoints
for GBS have been identified as a critical need for robust estimates
of effect in maternal GBS vaccine trials and studies of immune cor-
relates of protection [10]. In addition, considerations presented
here support collection of standardised data and sampling for
GBS disease in pregnant women, stillbirths and infants, to allow
meaningful comparisons across studies. More data on GBS disease
incidence are needed across geographical settings, particularly
Asia, but also sub-Saharan Africa, and in particular, West Africa [1].
1.2. Prioritization of clinical vaccine efficacy endpoints
Two main licensure pathways are being considered for mater-
nal GBS vaccines. One is demonstration of vaccine efficacy against
specific clinical endpoints, in randomized controlled trials. The
other is registration on the basis of vaccine immunogenicity with
immune correlates of protection against specific clinical disease
endpoints, established through seroepidemiological studies [9].
The former would provide gold standard evidence of protection
and an estimate of the overall public health impact of vaccination,
but would require a large and costly study, difficult to conduct in
the context of access to high standards of care [12]. A licensure
pathway based on immune correlates of protection may lead to
faster product availability, at reduced cost, without the need for
a very large pre-licensure trial. However, post licensure, introduc-
tion probe studies would still offer an opportunity to define public
health impact. For both validation of immunological correlates of
protection and for a vaccine efficacy trial, standard case definitions
and ascertainment methodologies are needed for specific clinical
disease endpoints. Guidance on immune correlates is beyond the
scope of this paper, and considered elsewhere [13].
Culture confirmed invasive GBS disease in young infants would
likely meet regulatory requirements as a highly specific primary
endpoint, with public health relevance. However, the relatively
low incidence of invasive infant GBS disease reported (in observa-
tional studies) means that this would require very large (approxi-
mately 70,000 pregnant women) clinical efficacy trials [12].
Invasive infant GBS disease is, however, likely substantially
under-reported in data from observational studies. The reported
incidence of any infant infectious disease depends on how the pop-
ulation denominator is defined, whether potential cases access
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health care (usually either through parental concern or referral by
community health workers in low-income settings), how cases are
clinically assessed, how cases are selected for biological sampling,
and how samples are taken and processed for a specific diagnosis
[14]. Variations in any of these factors affect case capture and
ascertainment, and bias estimates of disease incidence. The risk
of low case capture and under-ascertainment are highest in obser-
vational studies and surveillance in LMIC settings where access to
health care is usually more limited (care-seeking for neonates
ranges from 10 to 100%) [15], clinical staff are scarcer [16],
sample-taking is restricted by resources, and availability of quality
controlled laboratories to detect infection with appropriate meth-
ods is limited. For invasive infant GBS disease, low case capture is
likely to be particularly high, as many cases occur at, or within a
few hours, of birth, and there is rapid disease progression and a
high case fatality risk (e.g., 61% in the first 24 h after delivery for
neonatal GBS cases in a hospital in Kenya) [17]. Increasing case
capture and ascertainment of invasive infant GBS disease reduces
sample size requirements, but requires optimisation of methods
for case capture, clinical sampling and laboratory detection.
Invasive infant GBS disease is most common in the first few days
of life, and arises from ascending GBS infection from the maternal
genito-urinary tract. Fetal infection in utero presents with clinical
signs at, or shortly after, delivery. However, fetal demise may also
occur in utero, and the baby is stillborn as a result of GBS infection.
Recent work suggests 1–4% of all stillbirths (born with no signs of
life and 28 weeks’ gestation, or >1000 g birth weight) are associ-
ated with GBS [18,19], with recent studies in Kenya [17], Mozam-
bique [20] and South Africa (personal communication, Madhi, S.).
Sampling post-mortem of sterile sites offers the opportunity to
detect GBS-associated stillbirth. Furthermore, the same techniques
can be used to detect GBS disease in neonates and infants who have
died before reaching care and/or investigation for infection, which
can be used to increase detection of invasive GBS disease [21]. A pri-
mary composite endpoint of serious and fatal events associated
with GBS, including cases of invasive GBS disease in neonates,
infants and stillbirths would be highly relevant as a common entity,
better reflect true burden and reduce sample size requirements for
estimation of the effect of new interventions.
Additional endpoints for consideration include invasive mater-
nal GBS disease, as well as maternal and neonatal GBS colonisation,
and maternal GBS urinary tract infection. Maternal sepsis is a lead-
ing cause of maternal death, with much higher incidence in South
Asia and sub-Saharan Africa than in higher-income regions. Studies
in these settings show sepsis to account for 14% (95% confidence
interval [CI] 3%–36%) and 10% (95%CI 5.5, 18.5) of all maternal
deaths respectively [22], compared to 4.7% (95%CI 24, 111) in
high-income countries [22]. Worldwide, data on the aetiology of
maternal sepsis (often treated empirically) are limited, but GBS
has been shown to be a frequent contributor to maternal sepsis
in high-income countries [23–27]. It accounted for 25% of maternal
bacteraemia in Ireland [28] and 20% of puerperal bacteraemia in
the USA before implementation of screening and treatment guide-
lines [27]. Data on the incidence of GBS sepsis in pregnant and
postpartum women in LMICs are lacking, but it may be an impor-
tant contributor to maternal sepsis [29]. In contrast, maternal GBS
colonisation is known to be common, with 10–40% of pregnant
women colonised with GBS [30,31]. Of these, around 30–50% will
have newborns where GBS is detected shortly after birth [17]. In
the absence of intervention 1.1% (95% CI 0.6–1.5%) of newborns
born to women colonised with GBS will have EOGBS, decreasing
to 0.3% (0–0.9%) with high (80%) coverage of microbiological
screening during late pregnancy and administration of intrapartum
antibiotic prophylaxis [32]. The impact of vaccination on maternal
GBS colonisation will be important to characterize in terms of risk
of disease through exposure [33], and changes in circulating sero-
types, through serotype-specific reduction. Culture-confirmed
maternal GBS urinary tract infection could also be included as an
endpoint, particularly as it can precede invasive GBS disease in
mothers or the fetus. Additional clinical samples for diagnosis of
maternal chorioamnionitis, postpartum endometritis, and mastitis
may be of interest.
Here we suggest case capture and case ascertainment method-
ologies and definitions, prioritizing case ascertainment and case
definitions for the most specific and serious infections in the fetus,
neonate and young infant, aiming to provide a simple and prag-
matic approach applicable across settings (summarised in Table 1).
We also include invasive GBS disease in pregnant and postpartum
women, and specific details pertaining to maternal and neonatal
GBS colonisation (Panel 1) and maternal urinary tract infection.
However, intervention studies also provide an important opportu-
nity for vaccine probe-studies to investigate other adverse perina-
tal outcomes associated with maternal GBS colonisation and
ascending infection (with or without invasive disease), including
preterm birth and neonatal encephalopathy [3,34]. The recommen-
dations presented here are based on definitions identified in sys-
tematic literature reviews to estimate the burden of GBS disease
[29,30,32,35–41], discussion with an expert group convened by
the World Health Organization, and consideration of endpoints
used for other vaccine preventable childhood infections. The expert
working group reviewed drafts of case ascertainment methodolo-
gies and case definitions and we shared these with external stake-
holders for feedback.
2. Study methodologies and case ascertainment
2.1. Study design
A randomized controlled trial (RCT) with the most relevant clin-
ical endpoint would constitute the gold standard design for estima-
tion of vaccine efficacy (Table 1, Fig. 1), but the challenges for
maternal GBS vaccine trials are acknowledged. Observational stud-
ies and surveillance should ideally be conducted at the same level of
rigour as RCTs. For observational studies, therefore, case capture
would ideally be through recruitment of a cohort of pregnant
women, but without the intervention. However, this may not
always be feasible, and the use of population catchment or facility
birth denominators are pragmatic in surveillance, and can support
estimation of incidence of EOGBS and late onset GBS disease
(LOGBS). Where these strategies are used, assessment and/or miti-
gation of limitations should be considered. For studies using popu-
lation catchment estimates, selection bias can be approximated
through a health utilization survey. For studies in health facilities
and/or in the community, under-ascertainment can be reduced by
investigation of infant deaths, particularly in those who do not
reach care. Where facility births are used as a denominator, it is
important to consider and report that the disease incidence
observedmay not reflect the true population incidence, and/or case
fatality risk, as women delivering in the facilities are unlikely to be
representative of the general population in some settings, and case
fatality risks are likely to be lower, particularly in LMICs.
2.2. Study population for case capture
For vaccine efficacy studies (Table 1) it is essential to recruit
women during pregnancy, according to defined eligibility criteria,
randomise to receive the intervention or not, and follow up moth-
ers and newborns for at least 90 days after delivery. The primary
composite endpoint would include stillbirths and infants (0–
89 days) (Fig. 1). Characterization of post-abortion and post-
partum maternal outcomes would also be relevant. Inclusion of
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all these outcomes would be preferable in observational studies
too. Case capture can be increased in all study designs with a
defined schedule of follow-up visits after birth, and, most impor-
tantly (but most challenging) including the day of birth, whenmost
early deaths occur [42] and the majority (75–90%) of neonates with
early onset GBS (EOGBS) disease present [43]. Follow-up of infants
with invasive GBS disease (and appropriate controls) for at least
18 months is needed if neurodevelopmental impairment outcomes
are to be included, and this should be considered to better under-
stand the burden of long-term neurodevelopmental impairment
associated with invasive GBS disease in infancy.
2.3. Clinical characterisation – Neonates and infants
Systematic clinical assessment and sampling methods should
be implemented for observational studies and surveillance, as for
randomised controlled trials. Clinical algorithms are used to guide
empirical treatment for infants with possible serious bacterial
infection (pSBI), based on the presence of pre-specified clinical
signs (Table 2) [44,45]. Current guidelines suggest infants with
pSBI are referred to hospital [46], although outpatient treatment
may be offered where referral is not possible [47]. Using these
guidelines, health care workers should document the presence or
absence of specific clinical signs in accordance with international
guidelines, with flexibility to include additional documented signs
in accordance with local protocols. These should be used to guide
systematic clinical sampling, using an aseptic technique to sample
from sterile sites (blood and CSF). Sampling should be prior to
antibiotic administration, as long as this does not delay empirical
treatment. Antibiotic administration prior to sampling (e.g., when
given prior to hospital referral), contamination, and low blood vol-
umes decrease sensitivity of GBS detection using conventional cul-
ture methods.
Experience investigating neonatal deaths for GBS disease is cur-
rently limited. The CaDMIA and CaDMIA plus studies (Cause of
Death using Minimally Invasive Autopsies) have recently provided
data comparing minimally invasive tissue sampling (MITS, also ter-
med minimally invasive autopsy (MIA)), with complete diagnostic
autopsy (CDA) in Mozambique. In neonates, only three GBS infec-
tions were detected by CDA, and none by MITS [20]. In stillbirths,
three cases of GBS infection were identified by CDA and the same
three by MITS. Further data are awaited from ongoing studies in
seven sites across South Asia and sub-Saharan Africa as part of
the Child Health and Mortality Prevention Surveillance (CHAMPS)
network [48]. The CHAMPS protocol suggests including 1.5 mL
blood (sampled from the subclavian vein or the heart), liver tissue
(12 specimens), lung tissue samples (six chest punctures (both left
and right superior, mid and inferior chest wall), with four tissue
specimens from each entry point), CSF sampling and central ner-
vous system tissue samples (12 specimens obtained through occip-
ital, trans-nasal puncture and/or through the anterior fontanelle).
Where it is not acceptable, practical or feasible to undertake sam-
pling to this extent, for consistency with investigation of sick neo-
nates, we suggest blood and CSF sampling should be prioritised,
as well as the lung, where GBS is sequestered [49].
There is currently no established gold standard for the timing of
samples, but this should be as soon as possible after death, to
reduce the chance of post-mortem bacterial overgrowth resulting
in false positives. We suggest sampling within 24 h of death, in line
with the current CaDMIA plus and CHAMPS programmes. Sug-
gested timing and sample taking may need to be revised when
new data from CaDMIA plus and CHAMPS are available. Surface
GBS colonisation should not be considered sufficient to attribute
death to GBS disease.
2.4. Clinical characterisation – Stillbirths
There are limited data on case ascertainment of GBS associated
stillbirth, with the most recent studies from Kenya [17], Mozam-
bique [20], and South Africa (in progress). As GBS has been identi-
Table 1
Study methodologies and case ascertainment for invasive Group B Streptococcus (GBS) disease in pregnant, post-abortion and post-partum women, stillbirths and young infants
(0–89 days) for observational and clinical vaccine efficacy trials.
Observational epidemiological studies or
surveillance
Clinical vaccine efficacy trials
Study design Cohort studies with antenatal recruitment, and
follow-up through 89 days after delivery, are
preferred.
Surveillance can be used to provide incidence
data with denominators based on hospital
catchment population, or facility based births.
However, both are subject to bias which should
be assessed and reported.
Randomised controlled trial. Follow-up for efficacy at
least 89 days after delivery.
Study population for case capture Inclusion of stillbirths and infants (0–89 days)
preferred. Consider inclusion of pregnant, post-
abortion and post-partum women.
Inclusion of stillbirths, infants (0–89 days)
recommended for primary composite endpoint.
Consider inclusion of pregnant, post-abortion and post-
partum women for additional endpoints.
Clinical case definition Standardised clinical assessment using defined
clinical criteria preferred. Local adaptations
should be clearly reported.
Standardised clinical assessment and sampling based on
presence of defined clinical criteria essential.
Sampling
Sampling based on presence or absence of
clinical signs; samples collected with aseptic
technique, at recommended volumes
according to age/weight.
Post-mortem sampling recommended.
Sampling based on presence or absence of clinical signs;
samples collected with aseptic technique, at
recommended volumes according to age/weight.
Post-mortem sampling recommended.
Laboratory characterization Standardised operating procedures with
sensitive methods (automated blood cultures,
selective broth and agar).
Inclusion of culture independent diagnostic
tests where feasible.
All isolates stored, serotype and/or whole
genome sequencing where feasible.*
Standardised operating procedures with sensitive
methods (automated blood cultures, selective agar), and
quality assurance according to clinical development
stage.
Inclusion of culture independent diagnostic tests as
secondary endpoint.
All isolates stored,whole genome sequencing of isolates. *
* All GBS isolates should be typed or stored for later typing, ideally using whole genome sequencing.
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fied in both antepartum and intrapartum stillbirths, all stillbirths
meeting the WHO definition for stillbirth (born with no signs of life
28 weeks’ gestation or >1000 g) should be included in sampling
strategies for consistency across settings.
Sampling methods, to date, have been varied, including blood
(cord or heart), lung needle aspirate, minimally invasive autopsy
(blood, CSF and multiple organ sampling), and CDA [20]. Again,
more data are expected from CHAMPS and CaDMIA plus [48]. In
Fig. 1. Case ascertainment of invasive GBS disease in pregnant and post-partum women, stillbirths and infants (0–89 days). pSBI = possible serious bacterial infection;
CIDT = culture independent diagnostic tests. *Unless clinical contraindication. **GBS isolates should be stored, to allow later typing, ideally using whole genome sequencing. #
Dependent on establishment of specificity of the particular CIDT (based on nuclei acid amplification) used. ## Blood, cerebrospinal fluid and lung should be prioritised for
sampling.
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the interim, the CHAMPS protocol recommends samples of blood
(minimum 1.5 mL sampled from the subclavian vein or the heart),
lung, liver, central nervous system and CSF are taken as possible
after death, but within 24 h after delivery. As for neonates, where
sampling to this extent this is not acceptable, practical or feasible,
we suggest prioritizing blood, cerebrospinal fluid and lung.
2.5. Clinical characterisation – Pregnant, post-abortion and post-
partum women up to 42 days post delivery
A new WHO consensus definition for maternal sepsis has
recently been defined as a ‘‘life-threatening condition with organ
dysfunction resulting from infection during pregnancy, child-
birth, post-abortion, or postpartum period” [50]. Clinical criteria
are in the process of being validated for this diagnosis, and as a first
step will include identification of women with possible severe
maternal infection [50]. The diagnostic criteria for possible severe
maternal infectionmay serve as appropriate, sensitive clinical crite-
ria for sampling pregnant, post-abortion, and postpartum women
for maternal sepsis [50]. However, until standard clinical criteria
are determined, a simple, sensitive and pragmatic approach is
needed to guide case ascertainment for maternal GBS sepsis. We
suggest that all pregnant, post-abortion and postpartum women
up to 42 days after delivery with a temperature >38 C should be
investigated with blood sampling (for culture and culture-
independent diagnostic tests (CIDTs)), or where sepsis is clinically
suspected, or where there is a history of fever and clinical suspicion
of endometritis (abdominal pain or foul smelling vaginal discharge)
or chorioamnionitis [51]. This is suggested as a sensitive approach,
to maximise case detection. Specificity is provided through micro-
biological testing rather than clinical case definition only.
Maternal urinary tract infection can include asymptomatic bac-
teriuria, acute cystitis and pyelonephritis. Asymptomatic bacteri-
uria would only be detected through routine screening, but clinical
symptoms of acute cystitis (frequency, urgency, dysuria) or
pyelonephritis (fever, and flank pain, or nausea or vomiting, which
maybe associatedwith symptomsof acute cystitis) can direct inves-
tigation for urinary tract infection, to include a mid-stream urine
sample.
2.6. Laboratory characterisation – Detection
Microbiological methods should be sensitive and specific and at
present conventional cultures are the gold-standard, and are pre-
ferred to confirm cases as they have high specificity. CIDTs using
nucleic acid amplification methods may increase case ascertain-
ment, but this may be at the cost of specificity. This should be
assessed in existing CIDTs and those developed in future, including
the use of controls in observational studies [52]. Culture and isola-
tion of GBS also has the advantage that isolates can be assessed for
antibiotic susceptibility using standard methods and up-to-date
thresholds [53–55], and serotype based on capsular polysaccha-
ride, or using ST typing [56] and/or whole genome sequencing to
determine phylogeny and clonal complex type [57,58]. Sensitivity
of conventional microbiological culture methods should be opti-
mised through collection of appropriate sample volumes (based
on age and weight) prior to antibiotic administration, and automa-
tion of blood cultures to support standardisation.
2.7. Laboratory characterisation – Typing
Serotype identification for GBS was originally through capillary
precipitation (serotypes Ia, Ib, II, and III) [59], but latex agglutination
assays are now commercially available for 10 serotypes Ia/Ib/II-X
[60,61]. PCR and whole genome sequencing also allow serotype
assignment according to the genes present [62,63]. Althoughwhole
genome sequencing does not provide information on gene expres-
sion (which could become important if more GBS disease is caused
by serologically non-typeable GBS), it does enable detailed phyloge-
netic examination of multiple pathogen genomes, their evolution,
assessment of transmission, virulence factors and assessment of
any polymorphisms in the protein antigen sequence (for protein
vaccines), as well as the relationship between serotype, antimicro-
bial susceptibility31 and GBS clonal complex (CC-1, CC-10, CC-19,
CC-17 and CC-23), to be investigated. This latter pointwill be partic-
ularly important if serotype-specific vaccines are introduced, and
there is capsular switching in a virulent clone, such as clonal com-
plex 17, currently almost exclusively serotype III. It is also important
in order to detect protein antigen target polymorphism if protein
vaccines are trialled. GBS isolates should be stored for future charac-
terization if whole genome sequencing is not readily available.
3. Case definitions for invasive disease
3.1. Neonatal and young infant GBS disease
To confirm a case of GBS invasive disease (sepsis or meningitis),
there should be microbiological confirmation of GBS isolation from
Table 2
Case definitions for invasive Group B Streptococcus (GBS) disease in pregnant, post-abortion and post-partum women, stillbirths, neonates and young infants (0–89 days).
Case criteria Clinical criteria Laboratory criteria for confirmed GBS
disease*
Laboratory criteria for presumed GBS disease
(secondary case definitions)
Stillbirth (born with no
signs of life and
28 weeks’ gestation
or >1000 g body
weight)
Foetal demise. Isolation of GBS from blood, CSF, lung,
CNS or liver.
Culture independent diagnostic tests detect
GBS from blood, CSF, lung, CNS or liver.
Neonates and young
infants (through
89 days)
Infant death and/or 1 clinical signs of
possible serious bacterial infection:
 Temperature 37.5 ◦C or <35.5 C
 Tachypnoea (60 breaths per minute) or
severe chest indrawing or grunting or
cyanosis
 Change in level of activity
 History of feeding difficulty
 History of convulsions.
Isolation of GBS from blood or
cerebrospinal fluid in live infants and/or
isolation of GBS from blood, CSF, lung,
CNS or liver in infants who have died.
Culture independent diagnostic tests detect
GBS from blood or cerebrospinal fluid in live
infants, and/or from blood, CSF, lung, CNS or
liver in stillbirths or infants who have died.
Pregnant, post-abortion
and postpartum
women up to
42 days post delivery
Fever >38 C or clinical suspicion of sepsis, or
history of fever and signs of endometritis
(abdominal pain, or foul smelling vaginal
discharge) or chorioamniontis.
GBS isolated from maternal blood. GBS identified from culture independent
diagnostic tests from maternal blood.
* All GBS isolates should be typed or stored for later typing, ideally using whole genome sequencing.
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a sterile site in neonates/young infants with 1 clinical sign of pos-
sible serious bacterial infection, or death (Table 2). Sampling sites
to meet this definition should be blood or cerebrospinal fluid in live
infants, and blood, cerebrospinal fluid, central nervous system,
liver or lung in infants who have died (Table 2). This is consistent
with recent Brighton consensus guidelines on the diagnosis of
neonatal sepsis of all aetiologies, at Level 1 (best evidence) [11].
Presumed cases rely on the same demographic and clinical criteria,
but GBS is detected by culture independent diagnostic tests (CIDT)
from sterile sites as above, with defined specificity and sensitivity.
3.2. GBS-associated stillbirth
To confirm a case of GBS associated stillbirth (fetal disease), a
consistent approach with neonatal/infant disease should be taken,
with cases confirmed by post-mortem microbiological isolation of
GBS from a sterile body site (blood, cerebrospinal fluid, central ner-
vous system, lung or liver). Presumed cases are where GBS is
detected by CIDTs from usually sterile sites, with defined speci-
ficity and sensitivity. Isolation/detection of GBS from a surface or
placenta swab only would not be included as a case. Further
research is encouraged to define the role of histological evidence
of chorioamnionitis in the presence of a GBS positive placental sur-
face swab in case ascertainment.
3.3. Maternal GBS sepsis and urinary tract infection
To confirm a case of maternal GBS sepsis, there should be
microbiological isolation of GBS from blood of pregnant, post-
abortion and postpartum women up to 42 days after delivery with
fever (>38 C) or history of fever and clinical suspicion of
endometritis or chorioamnionitis. Presumed cases are where GBS
is detected by CIDTs from usually sterile sites, with defined speci-
ficity and sensitivity. For confirmation of urinary tract infection,
there should be microbiological isolation of >105 GBS colony form-
ing unit/mL from a mid-stream urine sample in symptomatic
women.
4. Conclusions
Our proposed case definitions and methods for case capture and
case ascertainment focus on confirmed invasive GBS disease in
stillbirths and infants, providing a framework for use in vaccine
efficacy trials, observational studies and surveillance. Key consid-
erations on additional endpoints including maternal outcomes
are also presented. The contribution of GBS to non-culture con-
firmed stillbirth and infant disease, as well as of GBS to preterm
birth and neonatal encephalopathy, may in the future be investi-
gated in vaccine probe studies.
High standard case capture and case characterization will likely
require capacity strengthening into infrastructures and know-how,
in resource-limited settings. Improved approaches to investigation
of infant deaths, particularly in the community, are required, and
the subject of current studies. The evidence provided will ulti-
mately support optimal policy decisions and appropriate use of
potentially life-saving new interventions.
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